TY - JOUR
T1 - Clinical and biomarker profiles and prognosis of elderly patients with coronavirus disease 2019 (COVID-19) with cardiovascular diseases and/or risk factors
AU - Matsumoto, Shingo
AU - Kuroda, Shunsuke
AU - Sano, Takahide
AU - Kitai, Takeshi
AU - Yonetsu, Taishi
AU - Kohsaka, Shun
AU - Torii, Sho
AU - Kishi, Takuya
AU - Komuro, Issei
AU - Hirata, Ken Ichi
AU - Node, Koichi
AU - Matsue, Yuya
N1 - Funding Information:
The authors acknowledge all the investigators who participated in CLAVIS-COVID (Supplementary Appendix) and the Japanese Circulation Society.
Funding Information:
T.Y. belongs to endowed departments of Abbott Vascular Japan, Boston Scientific Japan, Japan Lifeline, WIN International, and Takeyama KK. S. Kohsaka has received unrestricted research grants from the Department of Cardiology, Keio University School of Medicine provided by Daiichi Sankyo Co., Ltd. and Bristol-Meyers Squibb, as well as lecture fees from AstraZeneca and Bristol-Meyers Squibb. I.K. has received unrestricted research grants from Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Ltd., Idorsia Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Ono Pharmaceutical Co., Ltd., and Toa Eiyo Ltd., as well as lecture fees from AstraZeneca, Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., and Ono Pharmaceutical Co., Ltd. Y.M. is affiliated with a department endowed by Philips Respironics, ResMed, Teijin Home Healthcare, and Fukuda Denshi, and has received honoraria from Otsuka Pharmaceutical Co., Ltd. and Novartis Japan, consultant fees from Otsuka Pharmaceutical Co., Ltd., and joint research funds from Otsuka Pharmaceutical Co., Ltd. and Pfizer Inc.
Publisher Copyright:
© 2021 Japanese Circulation Society. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background: This study investigated the effects of age on the outcomes of coronavirus disease 2019 (COVID-19) and on cardiac biomarker profiles, especially in patients with cardiovascular diseases and/or risk factors (CVDRF). Methods and Results: A nationwide multicenter retrospective study included 1,518 patients with COVID-19. Of these patients, 693 with underlying CVDRF were analyzed; patients were divided into age groups (<55, 55-64, 65-79, and ≥80 years) and in-hospital mortality and age-specific clinical and cardiac biomarker profiles on admission evaluated. Overall, the mean age of patients was 68 years, 449 (64.8%) were male, and 693 (45.7%) had underlying CVDRF. Elderly (≥80 years) patients had a significantly higher risk of in-hospital mortality regardless of concomitant CVDRF than younger patients (P<0.001). Typical characteristics related to COVID-19, including symptoms and abnormal findings on baseline chest X-ray and computed tomography scans, were significantly less prevalent in the elderly group than in the younger groups. However, a significantly (P<0.001) higher proportion of elderly patients were positive for cardiac troponin (cTn), and B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP) levels on admission were significantly higher among elderly than younger patients (P<0.001 and P=0.001, respectively). Conclusions: Elderly patients with COVID-19 had a higher risk of mortality during the hospital course, regardless of their history of CVDRF, were more likely to be cTn positive, and had significantly higher BNP/NT-proBNP levels than younger patients.
AB - Background: This study investigated the effects of age on the outcomes of coronavirus disease 2019 (COVID-19) and on cardiac biomarker profiles, especially in patients with cardiovascular diseases and/or risk factors (CVDRF). Methods and Results: A nationwide multicenter retrospective study included 1,518 patients with COVID-19. Of these patients, 693 with underlying CVDRF were analyzed; patients were divided into age groups (<55, 55-64, 65-79, and ≥80 years) and in-hospital mortality and age-specific clinical and cardiac biomarker profiles on admission evaluated. Overall, the mean age of patients was 68 years, 449 (64.8%) were male, and 693 (45.7%) had underlying CVDRF. Elderly (≥80 years) patients had a significantly higher risk of in-hospital mortality regardless of concomitant CVDRF than younger patients (P<0.001). Typical characteristics related to COVID-19, including symptoms and abnormal findings on baseline chest X-ray and computed tomography scans, were significantly less prevalent in the elderly group than in the younger groups. However, a significantly (P<0.001) higher proportion of elderly patients were positive for cardiac troponin (cTn), and B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP) levels on admission were significantly higher among elderly than younger patients (P<0.001 and P=0.001, respectively). Conclusions: Elderly patients with COVID-19 had a higher risk of mortality during the hospital course, regardless of their history of CVDRF, were more likely to be cTn positive, and had significantly higher BNP/NT-proBNP levels than younger patients.
KW - Age
KW - B-type natriuretic peptide
KW - Cardiac troponin
KW - Cardiovascular disease
KW - Coronavirus disease 2019 (COVID-19)
UR - http://www.scopus.com/inward/record.url?scp=85107085583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107085583&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-21-0160
DO - 10.1253/circj.CJ-21-0160
M3 - Article
C2 - 33952834
AN - SCOPUS:85107085583
SN - 1346-9843
VL - 85
SP - 921
EP - 928
JO - Circulation Journal
JF - Circulation Journal
IS - 6
ER -